DEF 14A: Sensei Biotherapeutics Sets Date for 2024 Annual Stockholders Meeting

Sensei Biotherapeutics will hold its annual stockholders meeting virtually on June 11, 2024, to elect directors and ratify the selection of its independent accounting firm.

Summary

• Sensei Biotherapeutics, Inc. will hold its Annual Meeting of Stockholders on June 11, 2024, at 9:00 a.m. Eastern Daylight Time, accessible via live webcast.
• The meeting will address the election of Jessie English, James Peyer, and Thomas Ricks to the Board of Directors for terms expiring at the 2027 Annual Meeting.
• Stockholders will also vote to ratify the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is April 22, 2024.
• The proxy statement and annual report are available online at www.proxydocs.com/SNSE.
• Stockholders can vote online before and during the meeting, by telephone, or by mail.
• As of April 22, 2024, there were 25,080,958 shares of common stock outstanding and entitled to vote.
• The Board of Directors recommends voting for the election of all director nominees and for the ratification of Deloitte & Touche LLP.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions regarding voting matters. The sentiment is slightly positive due to the recommendations of the Board of Directors.

Positives

• The meeting will be held virtually, facilitating broader stockholder participation.
• Stockholders have multiple options for submitting their votes: online, by telephone, or by mail.
• The Board of Directors is recommending votes in favor of all proposals.

Future Outlook

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting.

Industry Context

This is a standard proxy statement for an annual meeting, covering routine corporate governance matters such as director elections and auditor ratification, which are typical for publicly traded companies.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, appears to be in line with industry standards for similarly sized biopharmaceutical companies.
• The company's approach to corporate governance, including board independence and committee structure, aligns with Nasdaq listing requirements and best practices.
• The fees paid to the independent auditor, Deloitte & Touche LLP, are consistent with those paid by other public companies of similar size and complexity.

Management Changes

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• Employees are indirectly impacted through the election of directors and the ratification of the accounting firm, which contribute to the overall governance and financial health of the company.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote their shares before the Annual Meeting.
• The company will file a report on Form 8-K within four business days after the Annual Meeting to disclose the final voting results.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Director Election, Deloitte & Touche LLP, Independent Auditor, Corporate Governance, Voting, Sensei Biotherapeutics